Boston, USA-Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has appointed Dr. Ian Braithwaite as Vice President, Global Project Management.
Novotech COO Michael Stibilj welcomed Dr. Braithwaite to the team, stating “Ian brings exceptional leadership and a strategic clinical background which will be pivotal in advancing our project management efforts”.
“He also brings extensive expertise in designing, implementing, and delivering global clinical programs, across various therapeutic areas, including oncology and rare diseases,” Stibilj said.
Dr. Braithwaite previously held several global roles, most recently as Senior Vice President & Therapeutic Business Unit Head at Worldwide Clinical Trials, where he demonstrated his ability to develop and implement business strategy, drive operational excellence, profitability and client satisfaction.
Prior to this, Dr. Braithwaite held senior leadership positions at other renowned organizations, including INC Research and PPD/Thermo Fisher Scientific, where he was instrumental in strategic growth initiatives and the development of clinical trial portfolios.
Ian expressed his delight to be joining Novotech and said he was honored to lead Global Project Management as the organization continues to expand its global footprint and capabilities to support its existing and future biotech clients.
Dr. Braithwaite remarked "I was drawn to Novotech by the team’s energy, passion and commitment to project delivery excellence throughout all phases of clinical development. I'm even more excited by the prospect of working with a group of dedicated professionals to deliver high quality global studies for the benefit of patients and our clients".
Dr. Baithwaite earned an Honours Degree and PhD in Pharmacology and Therapeutics at the University of Liverpool. He also holds a Post graduate Diploma in
Clinical Science from the Welsh School of Pharmacy and Pharmaceutical Sciences.
Media contact
Toyna Chin
About Novotech Novotech-CRO.com
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase.
With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations.
Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies.
Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results
For more information or to speak to an expert team member visit www.Novotech-CRO.com